Biotechs could save time, money from clinical trial rule change
The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.
- FDA is shifting the default Phase 3 requirement from two pivotal trials to one, potentially cutting years and money off the $2.6 billion, 10-15 year drug development process.
- The impact will be uneven: urgent diseases like ALS could benefit from faster single-trial approval, while high-placebo-response conditions like pain may struggle to prove efficacy with just one study.
- Smaller biotechs with limited funding but multiple drugs in development stand to gain the most from reduced trial requirements.
- FDA plans to offset reduced pre-approval testing with continued postmarket surveillance and new tools like AI and real-world data to maintain safety and precision.
The FDA plans to change its requirements for Phase 3 clinical trials, shifting from a default of two pivotal trials to one. This move aims to streamline the drug development process, which currently costs pharmaceutical companies an average of $2.6 billion and takes 10 to 15 years from discovery to approval. While some drugs may still need two trials based on the disease they target, biotech experts believe this change could significantly reduce time and costs for many companies, especially smaller ones with limited resources.
Experts highlight that the rule change won't impact all drugs equally. For diseases like ALS, where urgency is critical, conducting only one trial could expedite the availability of treatments. However, for conditions with high placebo rates, such as pain, proving efficacy with just one study may prove challenging. Smaller biotech firms stand to benefit the most, as they often juggle multiple drug developments but have limited funding. Reducing clinical trial requirements could allow them to bring more products to market without sacrificing quality.
Concerns about safety remain prominent. Experts are reassured by the FDA's continued commitment to postmarket surveillance and advancements in technology, such as AI and real-world data, that can enhance trial precision. Active communication between biotechs and the FDA will be essential to navigating these changes effectively. It's clear that while the rule change offers potential benefits, it also requires careful consideration of safety and efficacy standards.